• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    12/7/23 12:31:31 PM ET
    $BCLI
    $CCM
    $GTHX
    $KA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $BCLI alert in real time by email

    Gainers

    • Yield10 Bioscience (NASDAQ:YTEN) shares rose 104.4% to $0.46 during Thursday's regular session. The market value of their outstanding shares is at $5.4 million.
    • Solid Biosciences (NASDAQ:SLDB) stock rose 54.67% to $5.29. The market value of their outstanding shares is at $106.7 million.
    • Kewaunee Scientific (NASDAQ:KEQU) stock increased by 29.89% to $22.9. The market value of their outstanding shares is at $66.5 million. As per the press release, Q2 earnings came out yesterday.
    • G1 Therapeutics (NASDAQ:GTHX) stock increased by 22.1% to $2.96. The company's market cap stands at $153.1 million.
    • Know Labs (AMEX:KNW) shares rose 19.55% to $0.56. The company's market cap stands at $44.8 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) shares rose 19.13% to $1.37. The company's market cap stands at $4.9 million.

    Losers

    • Phio Pharma (NASDAQ:PHIO) shares declined by 40.3% to $0.95 during Thursday's regular session. The market value of their outstanding shares is at $2.3 million.
    • WAVE Life Sciences (NASDAQ:WVE) stock fell 30.21% to $4.79. The market value of their outstanding shares is at $474.9 million.
    • Kineta (NASDAQ:KA) stock decreased by 27.8% to $3.17. The market value of their outstanding shares is at $32.9 million.
    • Kintara Therapeutics (NASDAQ:KTRA) stock decreased by 18.64% to $0.23.
    • Brainstorm Cell (NASDAQ:BCLI) stock declined by 17.6% to $0.24. The market value of their outstanding shares is at $12.0 million.
    • Concord Medical Services (NYSE:CCM) stock fell 16.54% to $0.93. The company's market cap stands at $40.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BCLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCLI
    $CCM
    $GTHX
    $KA

    CompanyDatePrice TargetRatingAnalyst
    Wave Life Sciences Ltd.
    $WVE
    2/5/2026$38.00Buy
    BofA Securities
    Wave Life Sciences Ltd.
    $WVE
    12/12/2025$20.00 → $33.00Outperform
    Wedbush
    Wave Life Sciences Ltd.
    $WVE
    12/9/2025$27.00Sector Perform → Outperform
    RBC Capital Mkts
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    Wave Life Sciences Ltd.
    $WVE
    10/20/2025$18.00Overweight
    Wells Fargo
    Wave Life Sciences Ltd.
    $WVE
    8/4/2025$19.00Buy
    Canaccord Genuity
    Wave Life Sciences Ltd.
    $WVE
    7/28/2025$24.00Outperform
    Oppenheimer
    Wave Life Sciences Ltd.
    $WVE
    7/16/2025$16.00Buy
    Citigroup
    More analyst ratings

    $BCLI
    $CCM
    $GTHX
    $KA
    SEC Filings

    View All

    Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    2/27/26 4:24:56 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Wave Life Sciences Ltd.

    10-K - Wave Life Sciences Ltd. (0001631574) (Filer)

    2/26/26 7:50:51 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Wave Life Sciences Ltd.

    8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

    2/26/26 7:37:31 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CCM
    $GTHX
    $KA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 4:31:16 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 11:21:53 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 12, 2021 - FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy

    For Immediate Release: February 12, 2021 Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhi

    2/12/21 5:24:11 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CCM
    $GTHX
    $KA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Francis Chris exercised 33,194 units of Ordinary Shares at a strike of $4.28 and sold $499,593 worth of Ordinary Shares (33,194 units at $15.05) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    2/27/26 9:00:03 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Cumbo Alexander converted options into 30,031 shares and sold $96,923 worth of shares (16,644 units at $5.82), increasing direct ownership by 6% to 235,405 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/18/26 9:38:15 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Regulatory Officer Hanrahan Jessie converted options into 8,125 shares and sold $24,074 worth of shares (4,134 units at $5.82), increasing direct ownership by 6% to 74,318 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/18/26 9:34:09 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    $CCM
    $GTHX
    $KA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

    Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic

    3/5/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Live Presentation and Q&A: Monday, March 9, 2026 10 AM EDTCEO to Discuss INTASYL Platform and PH-762 Phase 1b Results King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities, followed by a live Q&A.Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral t

    3/5/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kewaunee Scientific and Nu Aire Inc. to Attend analytica 2026 in Munich

    STATESVILLE, N.C., March 3, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company will attend the 2026 analytica tradeshow and conference, taking place in Munich from March 24-27. Kewaunee will be joined by the Company's recently acquired subsidiary, Nu Aire, Inc. (NuAire), a proven leader in containment and biosafety technologies. Together, they will showcase a complete and complementary portfolio of laboratory infrastructure and safety-focused solutions designed to support the needs of modern lab environments worldwide.Established

    3/3/26 4:01:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $BCLI
    $CCM
    $GTHX
    $KA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gsk Plc bought $27,930,000 worth of Ordinary Shares (1,470,000 units at $19.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    12/15/25 4:32:10 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CCM
    $GTHX
    $KA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Wave Life Sciences with a new price target

    BofA Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $38.00

    2/5/26 9:31:24 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush reiterated coverage on Wave Life Sciences with a new price target

    Wedbush reiterated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $33.00 from $20.00 previously

    12/12/25 8:29:31 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Wave Life Sciences from Sector Perform to Outperform and set a new price target of $27.00

    12/9/25 8:38:23 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CCM
    $GTHX
    $KA
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

    King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed

    10/31/25 10:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in the o

    10/21/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CCM
    $GTHX
    $KA
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, as well as additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2026 Advancing regulatory engagement on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing) for AATD with feedback anticipated mid-2026; RestorAATion-2 clinical trial fully enrolled through 60

    2/26/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

    CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company's fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the

    2/19/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

    Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and preserved muscle, with once or twice-yearly dosing Generally safe and well tolerated with only mild treatment related adverse events and no clinically meaningful changes in clinical laboratory measur

    12/8/25 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CCM
    $GTHX
    $KA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

    SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 7:59:25 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

    SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

    11/14/24 3:24:53 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Solid Biosciences Inc.

    SC 13G - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 12:02:53 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care